An artistic rendering of blue neurons against a white background
Participant’s Diagnosis Halts Gene Therapy Clinical Trial
The FDA pauses the research program on a lentivirus-based treatment for a rare neurological condition after a patient developed a bone marrow disorder that could presage leukemia.
ABOVE: Reference
Participant’s Diagnosis Halts Gene Therapy Clinical Trial
Participant’s Diagnosis Halts Gene Therapy Clinical Trial

The FDA pauses the research program on a lentivirus-based treatment for a rare neurological condition after a patient developed a bone marrow disorder that could presage leukemia.

The FDA pauses the research program on a lentivirus-based treatment for a rare neurological condition after a patient developed a bone marrow disorder that could presage leukemia.

ABOVE: Reference
drug safety
Activities Discovered for Some Inactive Drug Ingredients
Ruth Williams | Jul 23, 2020
Screens of hundreds of drug excipients reveal that some can interact with biological targets, contradicting their FDA categorization as inert.
Doctor Who Blocked Thalidomide Dies
Kerry Grens | Aug 11, 2015
Frances Oldham Kelsey, a physician who halted use of a drug that caused birth defects in babies, has passed away at age 101.
Chronic Weed Use Shrinks Brain Region
Bob Grant | Nov 12, 2014
Long-term marijuana smokers have less gray matter in their orbitofrontal cortex than nonsmokers, but other brain circuits may compensate by increasing connectivity.
Epigenetic Cancer Therapy Clears Phase I
Tracy Vence | Apr 7, 2014
Investigational drug that inhibits proteins involved with epigenetic regulation shows activity against certain blood cancers in an early-stage clinical trial.
Opinion: Translational Biotechnology
John D. Loike and Jennifer E. Miller | Feb 17, 2014
Regulators must consider both the promise and potential pitfalls of new technologies when determining whether to move them into clinical trials.
FDA Considers Easing Controls on Diabetes Drug
Dan Cossins | Jun 11, 2013
A panel of advisors says that the agency should loosen restrictions on the sale of a diabetes drug with a spotty clinical safety record.
 
How Safe Is Your Medicine Cabinet?
Megan Scudellari | May 1, 2013
After numerous high-profile safety scares, clinicians and regulators push to fix critical weaknesses in the FDA’s monitoring system for approved drugs.
Opinion: Regenerating Safely
Dan Orlando | Jan 21, 2013
Patient safety is paramount in regulating new stem cell treatments.
Fears over Fast-Tracking Drugs
Edyta Zielinska | Sep 10, 2012
Doctors question whether a government initiative to speed approval for promising new drugs is ensuring safety.
Call for Diabetes Drug Ban
Sabrina Richards | Apr 30, 2012
A consumer advocacy group calls for a ban of a diabetes drug after evidence surfaces that it may increase the risk of cancer.
FDA Ups Recent Recalls
Bob Grant | Nov 9, 2011
The US regulatory agency recalled 54 percent more drugs from the second to third quarters of 2011.
Opinion: Sustainable Drug Monitoring
Jur Strobos and Andy Stergachis | Aug 31, 2011
Pharmacovigilance must keep pace with global distribution of drugs in resource-limited settings.
European Drug Agency Faces Scrutiny
Tia Ghose | Aug 4, 2011
Europe’s anti-fraud office has launched an investigation into potential conflicts of interest at the EU’s drug approval agency.